A clinical-stage gene therapy company announced Tuesday it has tapped an experienced in-house attorney to lead its legal team.

Cambridge, Massachusetts-based Voyager Therapeutics appointed Robert Hesslein as its general counsel. He will start in April.

“I am delighted to welcome Bob as our general counsel and latest member of our executive management team,” said Andre Turenne, Voyager's president and CEO. “Bob brings a wealth of legal and executive experience that will be invaluable as we continue to advance our efforts to develop needed therapies for patients suffering from severe neurological disorders.”

A company spokesperson did not respond to a request for further comment Tuesday.

Hesslein currently works for Massachusetts-based pharmaceutical company Foundation Medicine Inc., where he is the senior vice president and general counsel. He has served in that role since 2012. From 1996 to 2012, Hesslein served as the senior vice president and deputy general counsel of Genzyme Corp. He has also worked as senior vice president and counsel of investment company The New England and as an associate and partner at Csaplar & Bok. Hesslein graduated from the Cornell Law School.

Voyager focuses on finding treatments for severe neurological diseases, according to the press release.